Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 284 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Type 1 interferon Clear all

Conditions: Multiple Sclerosis, Optic Neuritis, Transverse Myelitis, Acute Brainstem/Cerebellar Syndrome
Interventions: interferon beta 1a 30 ug IM once weekly; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 20
States / cities: Derby, Connecticut • Tampa, Florida • Atlanta, Georgia + 16 more

Conditions: Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer, Malignant Mesothelioma, Pancreatic Cancer
Interventions: allogeneic tumor cell vaccine, autologous tumor cell vaccine, recombinant interferon alfa, recombinant interferon gamma, sargramostim, cyclophosphamide; Biological · Drug
Lead sponsor: St. Vincent Medical Center - Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections
Interventions: Interferon alfa-2a, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 6
States / cities: Los Angeles, California • Miami, Florida • New Orleans, Louisiana + 3 more

Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions: Interferon-1beta (Betaseron, BAY86-5046); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 19
States / cities: Many Locations, Alabama • Many Locations, Arizona • Many Locations, Delaware + 16 more

Conditions: Kidney Cancer
Interventions: recombinant interferon alfa, temsirolimus; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: New York, New York

Conditions: Bladder Cancer, Urethral Cancer
Interventions: Recombinant Interferon Alfa; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: recombinant interferon alfa, busulfan, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2000
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pancreatic Cancer
Interventions: Recombinant Interferon Alfa, Cisplatin, Fluorouracil, Radiation Therapy; Biological · Drug · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pancreatic Cancer
Interventions: recombinant interferon alfa, cisplatin, fluorouracil, radiation therapy, Resection of tumor; Biological · Drug · Radiation + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Multiple Sclerosis
Interventions: Avonex; Drug
Lead sponsor: Trinity Health Of New England; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Melanoma (Skin)
Interventions: Interferon alfa, Radiation therapy; Biological · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2005
U.S. locations: 2
States / cities: Miami, Florida • Tampa, Florida

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: carmustine, cyclophosphamide, dexamethasone, etoposide, filgrastim, mitoxantrone hydrochloride, recombinant interferon alfa, sargramostim, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy; Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 70 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hepatitis C
Interventions: interferon alfa-2b, peginterferon alfa-2b, ribavirin, USP, external drug infusion pump; Drug · Device
Lead sponsor: Medtronic Corporate Technologies and New Ventures; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Melanoma (Skin)
Interventions: recombinant interferon alfa, radiation therapy; Biological · Radiation
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 23
States / cities: Atlanta, Georgia • Decatur, Georgia • Chicago, Illinois + 15 more

Conditions: Malignant Mesothelioma
Interventions: recombinant interferon alfa, cisplatin, surgical procedure, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2000
U.S. locations: 3
States / cities: Marrero, Louisiana • Philadelphia, Pennsylvania • Newport News, Virginia

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Interferon beta-1b (Betaseron, BAY86-5046); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 51
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 47 more

Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Recurrent Intraocular Melanoma
Interventions: recombinant interferon alfa-2b, dacarbazine, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Not listed
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions: EC Aspirin, Radical Prostatectomy, Recombinant Interferon Alfa-2b, Rintatolimod; Drug · Procedure · Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: recombinant interferon alfa, sargramostim, cyclophosphamide, dexamethasone, melphalan, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: University of Tennessee; Other
Eligibility: 19 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2004
U.S. locations: 4
States / cities: Memphis, Tennessee

Conditions: Active Ulcerative Colitis
Interventions: BG9418 (Interferon beta-1a), Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 5
States / cities: Birmingham, Alabama • Lakewood, Colorado • Bristol, Connecticut + 2 more

Conditions: Kidney Cancer
Interventions: aldesleukin, recombinant interferon alfa, conventional surgery; Biological · Procedure
Lead sponsor: Blumenthal Cancer Center at Carolinas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Multiple Sclerosis
Interventions: Interferon beta-1a (current approved manufacturing process invloving FBS), Interferon beta-1a (new process, manufactured without FBS); Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Prostate Cancer
Interventions: recombinant interferon alfa, estramustine phosphate sodium, isotretinoin, mitoxantrone hydrochloride, paclitaxel, vinorelbine ditartrate; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 19
States / cities: Denver, Colorado • Atlanta, Georgia • Decatur, Georgia + 16 more

Conditions: Leukemia
Interventions: recombinant interferon alfa, cytarabine, imatinib mesylate; Biological · Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: East Hanover, New Jersey

Search by objective public record fields.

Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease

Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron

Chemotherapy and Biological Therapy in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium

Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma

Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer

Chemoradiation in Locally Advanced Pancreatic Cancer

Assessing Tolerability of Avonex Intramuscular Injections

Post-Operative Adjuvant Radiotherapy With Concurrent Interferon-Alfa

Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma

Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C

Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin

Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma

BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose

Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance

Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery

Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma

A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis

Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers

Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia